Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 1/2018

01-02-2018 | Original Article

Comparison of nomograms predicting lymph node invasion in patients undergoing radical prostatectomy for prostate cancer

Authors: G. J. Nason, E. M. O’Connor, D. MacMahon, B. Moss, S. W. Considine, A. Cahill, C. O’Rourke, F. M. O’Brien

Published in: Irish Journal of Medical Science (1971 -) | Issue 1/2018

Login to get access

Abstract

Introduction

The aim of this study was to compare the performance of preoperative risk nomograms or detecting lymph node invasion in a cohort of men undergoing radical prostatectomy (RP).

Methods

A retrospective analysis was performed on all men (n = 145) who underwent RP between 2012 and 2015. Preoperative data was inputted to the Memorial Sloan-Kettering Cancer Centre (MSKCC), Partin 2011 and Briganti nomograms and the University of California San Francisco- Centre of the Prostate Risk Assessment tool (UCSF-CAPRA). The risk of lymph node involvement (LNI) was calculated and compared to final histology.

Results

One hundred three (71%) men underwent a lymph node dissection at RP. Ten (9.7%) demonstrated LNI. The median nodal yield was 15 nodes, with no difference between those with LNI and those without (19.5 vs 14.5, p = 0.22).No patient classified as low risk on the UCSF-CAPRA score had evidence of LNI. In patients with LNI, no patient breached the 2% threshold for lymph node dissection (LND) on the MSKCC nomogram; four patients breached the 5% threshold on the Partin tables while three patients breached the 2.5% threshold for the Briganti nomogram.

Conclusion

Nomograms produce useful information regarding risk of disease; however, they often have not been validated on different populations. Risk predictions need to be considered carefully and treatment decisions were made on a patient specific basis.
Literature
1.
2.
go back to reference Briganti A, Blute ML, Eastham JH et al (2009) Pelvic lymph node dissection in prostate cancer. Eur Urol 55:1251–1265CrossRefPubMed Briganti A, Blute ML, Eastham JH et al (2009) Pelvic lymph node dissection in prostate cancer. Eur Urol 55:1251–1265CrossRefPubMed
3.
go back to reference Masterson TA, Bianco FJ Jr, Vickers AJ et al (2006) The association between total and positive lymph node counts, and disease progression in clinically localised prostate cancer. J Urol 175:1320–1324CrossRefPubMedPubMedCentral Masterson TA, Bianco FJ Jr, Vickers AJ et al (2006) The association between total and positive lymph node counts, and disease progression in clinically localised prostate cancer. J Urol 175:1320–1324CrossRefPubMedPubMedCentral
4.
go back to reference Joslyn SA, Konety BR (2006) Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 68:121–125CrossRefPubMed Joslyn SA, Konety BR (2006) Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 68:121–125CrossRefPubMed
5.
go back to reference Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65:124–137CrossRefPubMed Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65:124–137CrossRefPubMed
6.
go back to reference Graefen M (2006) In which patients with prostate cancer should we perform a lymph-node dissection? Eur Urol 50:278–279CrossRefPubMed Graefen M (2006) In which patients with prostate cancer should we perform a lymph-node dissection? Eur Urol 50:278–279CrossRefPubMed
7.
go back to reference Abdollah F, Schmitges J, Sun M et al (2011) A critical assessment of the value of lymph node dissection at radical prostatectomy: a population-based study. Prostate 71:1587–1594PubMed Abdollah F, Schmitges J, Sun M et al (2011) A critical assessment of the value of lymph node dissection at radical prostatectomy: a population-based study. Prostate 71:1587–1594PubMed
8.
go back to reference Briganti A, Chun FK, Salonia A et al (2006) Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 49:1019–1026CrossRefPubMed Briganti A, Chun FK, Salonia A et al (2006) Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 49:1019–1026CrossRefPubMed
9.
go back to reference Cagiannos I, Karakiewicz P, Eastham JA et al (2003) A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 170:1798–1803CrossRefPubMed Cagiannos I, Karakiewicz P, Eastham JA et al (2003) A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 170:1798–1803CrossRefPubMed
10.
go back to reference Partin AW, Mangold LA, Lamm DM et al (2001) Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 58:843–848CrossRefPubMed Partin AW, Mangold LA, Lamm DM et al (2001) Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 58:843–848CrossRefPubMed
11.
go back to reference Makarov DV, Trock BJ, Humphreys EB et al (2007) Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69:1095–1101CrossRefPubMedPubMedCentral Makarov DV, Trock BJ, Humphreys EB et al (2007) Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69:1095–1101CrossRefPubMedPubMedCentral
12.
go back to reference Briganti A, Larcher A, Abdollah F et al (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61:480–487CrossRefPubMed Briganti A, Larcher A, Abdollah F et al (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61:480–487CrossRefPubMed
13.
go back to reference Suardi N, Larcher A, Haese A et al (2014) Indication for and extension of pelvic lymph node dissection during robotic-assisted radical prostatectomy: an analysis of five European institutions. Eur Urol 66:635–643CrossRefPubMed Suardi N, Larcher A, Haese A et al (2014) Indication for and extension of pelvic lymph node dissection during robotic-assisted radical prostatectomy: an analysis of five European institutions. Eur Urol 66:635–643CrossRefPubMed
14.
go back to reference Kawakami J, Meng MV, Sadetsky N et al (2006) Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE. J Urol 176:1382–1386CrossRefPubMed Kawakami J, Meng MV, Sadetsky N et al (2006) Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE. J Urol 176:1382–1386CrossRefPubMed
15.
go back to reference Schiffmann J, Haese A, Leyh-Bannurah SR et al (2015) Adherence of the indication to Euroepan Assocaition of Urology guideline recommended pelvic lymph node dissection at high volume center: differences between open and robot-assisted radical prostatectomy. Eur J Surg Oncol 4:1547–1553CrossRef Schiffmann J, Haese A, Leyh-Bannurah SR et al (2015) Adherence of the indication to Euroepan Assocaition of Urology guideline recommended pelvic lymph node dissection at high volume center: differences between open and robot-assisted radical prostatectomy. Eur J Surg Oncol 4:1547–1553CrossRef
16.
go back to reference Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167:1681–1686CrossRefPubMed Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167:1681–1686CrossRefPubMed
17.
go back to reference Walz J, Bladou F, Rousseau B et al (2012) Head to head comparison of nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended pelvic lymph node dissection. Urology 79:546–551CrossRefPubMed Walz J, Bladou F, Rousseau B et al (2012) Head to head comparison of nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended pelvic lymph node dissection. Urology 79:546–551CrossRefPubMed
18.
go back to reference Touijer K, Rabbani F, Otero JR et al (2007) Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. J Urol 178:120–124CrossRefPubMed Touijer K, Rabbani F, Otero JR et al (2007) Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. J Urol 178:120–124CrossRefPubMed
19.
go back to reference Abdollah F, Schmitges J, Sun M et al (2011) Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy. Urology 78:1363–1367CrossRefPubMed Abdollah F, Schmitges J, Sun M et al (2011) Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy. Urology 78:1363–1367CrossRefPubMed
20.
go back to reference de Jong IJ, Pruim J, Elsinga PH et al (2003) Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 44:331–335PubMed de Jong IJ, Pruim J, Elsinga PH et al (2003) Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 44:331–335PubMed
21.
go back to reference Thoeny HC, Triantafyllou M, Birkhaeuser FD et al (2009) Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 55:761–769CrossRefPubMed Thoeny HC, Triantafyllou M, Birkhaeuser FD et al (2009) Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 55:761–769CrossRefPubMed
22.
go back to reference Winter A, Kneib T, Henke RP et al (2014) Sentinel lymph node dissection in more than 1200 prostate cancer cases: rate and prediction of lymph node involvement depending on preoperative tumor characteristics. Int J Urol 21:58–63CrossRefPubMed Winter A, Kneib T, Henke RP et al (2014) Sentinel lymph node dissection in more than 1200 prostate cancer cases: rate and prediction of lymph node involvement depending on preoperative tumor characteristics. Int J Urol 21:58–63CrossRefPubMed
Metadata
Title
Comparison of nomograms predicting lymph node invasion in patients undergoing radical prostatectomy for prostate cancer
Authors
G. J. Nason
E. M. O’Connor
D. MacMahon
B. Moss
S. W. Considine
A. Cahill
C. O’Rourke
F. M. O’Brien
Publication date
01-02-2018
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 1/2018
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-017-1626-8

Other articles of this Issue 1/2018

Irish Journal of Medical Science (1971 -) 1/2018 Go to the issue

Historical and Literary

Margins of viability

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.